The compound 1-MT can inhibit IDO, leading to a restructured granuloma with a higher recruitment of T cells to the core of the lesion, suggesting its potential as a supplementary treatment alongside anti-TB chemotherapy in clinical settings (Singh et al., 2023). Here, IDO1 is linked to tuberculosis.